Worsening anxiety and depression after initiation of lumacaftor/ivacaftor combination therapy in adolescent females with cystic fibrosis

J Cyst Fibros. 2017 Jul;16(4):525-527. doi: 10.1016/j.jcf.2017.05.008. Epub 2017 Jun 8.

Abstract

In both phase III studies of LUM/IVA, as well as an extension study, worsening of mental health was not reported as a common side effect. Here we describe five cases in adolescent female patients that suggest a worsening of anxiety or depression associated with its use. In these five patients, two experienced suicidal ideation and three made suicide attempts that resulted in psychiatric hospitalizations.

Keywords: CFTR modulator; Cystic fibrosis.

Publication types

  • Case Reports

MeSH terms

  • Adolescent
  • Aminophenols* / administration & dosage
  • Aminophenols* / adverse effects
  • Aminopyridines* / administration & dosage
  • Aminopyridines* / adverse effects
  • Antidepressive Agents / administration & dosage*
  • Anxiety* / chemically induced
  • Anxiety* / diagnosis
  • Anxiety* / drug therapy
  • Benzodioxoles* / administration & dosage
  • Benzodioxoles* / adverse effects
  • Child
  • Cognitive Behavioral Therapy / methods*
  • Cystic Fibrosis* / drug therapy
  • Cystic Fibrosis* / psychology
  • Depression* / chemically induced
  • Depression* / diagnosis
  • Depression* / drug therapy
  • Drug Combinations
  • Female
  • Humans
  • Membrane Transport Modulators / administration & dosage
  • Membrane Transport Modulators / adverse effects
  • Quinolones* / administration & dosage
  • Quinolones* / adverse effects
  • Suicidal Ideation
  • Suicide, Attempted / prevention & control*
  • Withholding Treatment

Substances

  • Aminophenols
  • Aminopyridines
  • Antidepressive Agents
  • Benzodioxoles
  • Drug Combinations
  • Membrane Transport Modulators
  • Quinolones
  • lumacaftor, ivacaftor drug combination